Top Story Today
The $2.3B Drug That's Not Quite an ADC
Regeneron committed up to $2.3 billion for Parabilis Medicines and its Helicon platform, a class of stabilized peptides that slip inside cells like molecular spies to neutralize "undruggable" cancer targets. Unlike traditional ADCs (which act like guided missiles carrying toxic payloads), Helicons sit in a sweet spot between small molecules and antibodies, capable of blocking protein interactions, triggering targeted degradation, or delivering radioisotopes. Days later, Parabilis filed for a record-breaking $670 million biotech IPO.
Why it matters: The deal signals that big pharma's ADC shopping spree is evolving beyond better linkers and stronger poisons. Regeneron is assembling a next-gen toolkit of modalities that can reach intracellular targets no traditional conjugate has ever touched, a strategic bet that differentiation, not iteration, wins the oncology arms race.
Read more →Clinical Wins & Losses
Roche Beat Both KRAS Rivals. At the Same Time.
Roche's divarasib beat both Amgen's Lumakras and BMS's Krazati in a head-to-head Phase 3 trial, hitting progression-free survival and overall survival with statistical significance. Most companies never risk running against approved competitors directly. Roche did it against two at once and won, positioning divarasib as the likely new standard of care in KRAS G12C lung cancer.
Read more →Regeneron's Melanoma Combo Missed Keytruda by a Hair
Five extra months of progression-free survival over Keytruda, but a p-value of 0.0627 instead of the required 0.05. Wall Street erased 11% of Regeneron's market cap, and analysts zeroed out $1.8 billion in projected peak sales. In oncology, close doesn't count.
Read more →BioMarin's $270M Rare Disease Bet Hits a Wall
BioMarin's enzyme replacement therapy nailed its biochemical target (raising PPi levels significantly) but failed to improve bone healing in children with ENPP1 deficiency. The company paid $270 million for Inozyme with no milestone protections. It's the rare disease equivalent of filling the gas tank while the engine refuses to start.
Read more →FcRn Inhibitors Can't Crack Thyroid Eye Disease
Immunovant killed its batoclimab program after two Phase 3 trials failed in thyroid eye disease. Argenx also pulled its TED studies earlier. The pattern suggests that vacuuming antibodies from the bloodstream can't fix a compartmentalized disease hiding behind the eye's biological fortress.
Read more →Deals & Strategy
17 Pharma Giants Trade Discounts for Tariff Protection
Amgen, BMS, Merck, and other drugmakers signed voluntary pricing deals with the Trump administration: deep discounts on select drugs for Medicaid and cash-paying patients in exchange for three-year tariff exemptions. Seventeen pharma companies total signed the deals. Stocks went up because Wall Street read it as regulatory risk reduction, not revenue destruction. The real story is the precedent being built for future negotiations.
Read more →Lilly Pays $202M for a Protein That Smuggles DNA Past Your Immune System
Eli Lilly acquired preclinical startup Engage Biologics and its Tethosome platform, which sneaks therapeutic DNA into cells while dodging immune sensors that normally trigger inflammation. The technology claims 100-fold better gene expression than standard non-viral delivery. It's the latest piece in Lilly's $20 billion-plus genetic medicine shopping spree.
Read more →Science & Infrastructure
The 40-Year Treatment Drought Two Companies Are Racing to End
Patients with alpha-1 antitrypsin deficiency have had the same IV infusion since 1987. Now Sanofi's next-gen protein therapy tripled AAT levels versus standard care, while Wave's RNA editor reduced toxic protein by 70% and restored the body's natural infection-response surge. Two radically different approaches; same finish line.
Read more →Denmark's $861M Play to Become Europe's Biotech Capital
The Novo Nordisk Foundation committed $861 million over a decade to Copenhagen's BioInnovation Institute, its largest donation ever. The funding expands beyond traditional biotech into AI and quantum computing, betting that the next wave of drug breakthroughs will come from biology plus computation. It's one small country's very expensive bet that Europe's biotech future doesn't have to be built in Boston.
Read more →